MOTS-c: Mitochondrial-Derived Peptide

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide (MRWQEMGYIFYPRKLR) encoded within the mitochondrial genome. Discovered by Changhan David Lee and colleagues at the University of Southern California in 2015, MOTS-c was the first mitochondrial-derived peptide (MDP) shown to have significant metabolic regulatory activity.

The discovery of MOTS-c challenged the traditional view of mitochondria as simple energy-producing organelles. MOTS-c is encoded within the 12S ribosomal RNA gene of mitochondrial DNA and acts as a retrograde signaling molecule — meaning it carries information from the mitochondria to the nucleus, influencing nuclear gene expression. This places MOTS-c at the intersection of mitochondrial biology, metabolic regulation, and the emerging field of mitochondrial-nuclear communication.

MOTS-c has a molecular weight of approximately 2,174 Da and is detectable in circulating plasma, skeletal muscle, and other tissues. Its levels decline with age in both rodent and human samples, correlating with age-related changes in metabolic function.

MOTS-c operates through a distinctive mechanism that involves metabolic reprogramming and nuclear translocation.

**AMPK activation:** MOTS-c activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation shifts cellular metabolism from anabolic (growth/storage) toward catabolic (energy-producing) pathways. In cell culture models, MOTS-c treatment increases glucose uptake, enhances fatty acid oxidation, and suppresses de novo lipogenesis. The AMPK activation appears to result from MOTS-c's interference with the folate-methionine cycle, which alters the cellular ratio of AMP to ATP.

**Nuclear translocation:** Under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it interacts with chromatin and regulates gene expression. This was demonstrated by the Lee laboratory using immunofluorescence and chromatin immunoprecipitation in cell models subjected to glucose restriction and oxidative stress. Nuclear MOTS-c binds to antioxidant response elements (ARE) and regulates genes involved in cellular stress defense.

**Folate cycle interference:** MOTS-c inhibits the folate cycle, specifically the enzyme MTHFD2 (methylenetetrahydrofolate dehydrogenase 2), leading to accumulation of the metabolic intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). AICAR is an endogenous AMPK activator, providing the mechanistic link between MOTS-c and AMPK signaling.

**Exercise mimetic properties:** The combination of AMPK activation, enhanced glucose utilization, and fatty acid oxidation has led researchers to characterize MOTS-c as an "exercise mimetic" — a compound that recapitulates some of the metabolic effects of physical exercise at the cellular level.

MOTS-c research has expanded rapidly since its discovery in 2015.

MOTS-c belongs to a growing family of mitochondrial-derived peptides (MDPs) that serve as retrograde signaling molecules.

**Humanin** — Discovered in 2001, Humanin is a 24-amino acid peptide encoded in the 16S rRNA region of mitochondrial DNA. It is primarily studied for neuroprotective and cytoprotective effects, acting through the STAT3 signaling pathway and the formyl peptide receptor. While both MOTS-c and Humanin decline with age, they operate through distinct mechanisms — MOTS-c through AMPK/metabolic pathways, Humanin through STAT3/survival pathways.

**SHLP peptides (SHLPs 1-6)** — Six small humanin-like peptides also encoded in the 16S rRNA region. They have various reported activities including insulin sensitization (SHLP2, SHLP3) and cellular stress protection. Less extensively characterized than MOTS-c or Humanin.

The existence of multiple bioactive peptides encoded within mitochondrial DNA suggests that the mitochondrial genome functions not just as a blueprint for oxidative phosphorylation components, but as an active signaling center that communicates cellular energy status to the nucleus. This "mitochondria as signaling organelle" paradigm is one of the most significant conceptual advances in cell biology in recent years.

MOTS-c research requires attention to several methodological factors:

**Peptide handling:** MOTS-c contains a methionine residue at position 1 and a tryptophan at position 4, both susceptible to oxidation. Minimize air exposure during reconstitution, use nitrogen-flushed vials when possible, and store reconstituted solutions at 2-8°C for no more than 7-10 days. Lyophilized material is stable at -20°C for 12-18 months.

**In-vitro concentrations:** Published cell culture studies use MOTS-c at 1-100 micromolar, with 10 micromolar being a common working concentration. AMPK phosphorylation is typically detectable within 30-60 minutes of treatment, while gene expression changes require 4-24 hours.

**In-vivo protocols:** Rodent studies typically administer MOTS-c at 5-15 mg/kg intraperitoneally, either daily or three times weekly. Metabolic endpoints (glucose tolerance, insulin sensitivity) are assessed after 1-2 weeks of administration. Physical performance endpoints require longer treatment periods (4-8 weeks).

**Key readouts:** AMPK phosphorylation (Western blot), glucose uptake (2-NBDG fluorescent assay), fatty acid oxidation (Seahorse XF analyzer), and nuclear translocation (immunofluorescence) are the core assays for characterizing MOTS-c activity in a new experimental system.

*All materials are for research use only.*